Subscribe To
Context therapeutics announces poster presentation at upcoming 2022 asco annual meeting
Context Therapeutics (NASDAQ:CNTX) Inc has told investors that an abstract on the results of the monotherapy...
May 5, 2022, 10:02 am
Atreca: biotech with promise based on first candidate atrc-101
Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients (66%) who took ATCR-101 with H-score...
April 22, 2022, 1:14 pm
Repare therapeutics shares dip after updated rp-3500 data in solid tumors
Repare Therapeutics Inc (NASDAQ: RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synt...
April 12, 2022, 9:48 am
Rubius shares plunge after early data from rtx-240 solid tumor trial
Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase...
April 8, 2022, 2:19 pm
Clovis oncology's rubraca significantly improves pfs in ovarian cancer regardless of biomarker status
Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase...
March 31, 2022, 9:34 am
Global blood therapeutics' oxbryta scores european approval for sickle cell disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...
February 16, 2022, 9:41 am
Global blood therapeutics' oxbryta scores european approval for sickle cell disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...
February 16, 2022, 9:41 am
Global blood therapeutics' oxbryta scores european approval for sickle cell disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...
February 16, 2022, 9:41 am
Sierra oncology: plenty of room to trade higher after latest myelofibrosis data
Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of ...
January 26, 2022, 5:11 pm
Sierra oncology: plenty of room to trade higher after latest myelofibrosis data
Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of ...
January 26, 2022, 5:11 pm
Sierra oncology: plenty of room to trade higher after latest myelofibrosis data
Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of ...
January 26, 2022, 5:11 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...
January 21, 2022, 12:14 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...
January 21, 2022, 12:14 pm
Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...
January 21, 2022, 12:14 pm
Nuvation (nuvb) gets fda clearance for oncology candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination wi...
January 21, 2022, 11:35 am
Nuvation (nuvb) gets fda clearance for oncology candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination wi...
January 21, 2022, 11:35 am
Nuvation (nuvb) gets fda clearance for oncology candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination wi...
January 21, 2022, 11:35 am
Sqz biotechnologies' cell therapy shows favorable safety profile in hpv+ solid tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy ...
December 2, 2021, 1:31 pm
Sqz biotechnologies' cell therapy shows favorable safety profile in hpv+ solid tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy ...
December 2, 2021, 1:31 pm
Sqz biotechnologies' cell therapy shows favorable safety profile in hpv+ solid tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy ...
December 2, 2021, 1:31 pm